The pharmacological treatment of autistic spectrum disorders

CNS Spectrums

Volumn 7, Issue 9, 2002, Pages 663-669

  Owley, Thomas ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ANTICONVULSIVE AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BARBITURIC ACID DERIVATIVE; CARBAMAZEPINE; CENTRAL STIMULANT AGENT; CLOMIPRAMINE; CLONIDINE; DESIPRAMINE; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LAMOTRIGINE; LITHIUM; METHYLPHENIDATE; NALTREXONE; NEUROLEPTIC AGENT; OLANZAPINE; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PYRIDOXINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIFLUOPERAZINE; UNINDEXED DRUG; VALPROIC ACID;

APPETITE DISORDER; ATTENTION DEFICIT DISORDER; AUTISM; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DOSE RESPONSE; GINGIVA HYPERTROPHY; HIRSUTISM; HUMAN; HYPERACTIVITY; INSOMNIA; IRRITABILITY; MEDICAL DECISION MAKING; MOTOR DYSFUNCTION; NAUSEA; PRIORITY JOURNAL; RESTLESSNESS; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; TARDIVE DYSKINESIA; TIC; VOMITING; WEIGHT GAIN;

EID: 0037972126     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S109285290002215X     Document Type: Review

References (88)

1. Cook EH, Jr., Rowlett R, Jaselskis C, Leventhal BL. Fluoxetine treatment of children and adults with autistic disorder and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31739-745.
2. Gordon C, State R, Nelson J, Hamburger S, Rapoport J. A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry. 1993;50:441-447.
3. Awad GA. The use of selective serotonin reuptake inhibitors in young children with pervasive developmental disorders: some clinical observations. Can J Psychiatry. 1996;41:361-366.
4. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH. Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol. 1997;7:109-121.
5. McDougle CJ, Epperson CN, Price LH, Gelernter J. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry. 1998;3:270-273.
6. Posey DJ, Walsh KH, Wilson GA, McDougle CJ. Risperidone in the treatment of two very young children with autism. J Child Adolesc Psychopharmacol. 1999;9:273-276.
7. Ghaziuddin M, Tsai L, Ghaziuddin N. Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry. 1991;30:508-509.
8. Kroenke K, West SL, Swindle R, Gilsenan A, Eckert GJ, Dolor R, et al. Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA. 2001;286:2947-2955.
9. Goodman WK, McDougle CJ, Price LH. Pharmacotherapy of obsessive-compulsive disorder. J Clin Psychiatry. 1992;53(suppl):29-37.
10. Remington G, Sloman L, Konstantareas M, Parker K, Gow R. Clomipramine versus haloperidol in the treatment of autistic disorder: a double-blind, placebo-controlled, crossover study. J Clin Psychopharmacol. 2001;21:440-444.
11. Cook E, Rowlett R, Jaselskis C, Leventhal B. Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry. 1992;31:739-745.
12. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P. Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry. 1996;57:333-336.
13. Posey DJ, McDougle CJ. Pharmacotherapeutic management of autism. Expert Opin Pharmacother. 2001;2:587-600.
14. Cook E, Leventhal B. The serotonin system in autism. Curr Opin Pediatr. 1996;8:348-354.
15. Aman MG, Van Bourgondien ME, Wolford PL, Sarphare G. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use. J Am Acad Child Adolesc Psychiatry. 1995;34:1672-1681.
16. Martin A, Scahill L, Klin A, Volkmar FR. Higher-functioning pervasive developmental disorders: rates and patterns of psychotropic drug use. J Am Acad Child Adolesc Psychiatry. 1999;38:923-931.
17. Klin A, Volkmar F, Schultz R, Pauls D, Cohen DJ. Asperger's syndrome: phenomenology, neuropsychology, and neurobiology. Paper presented at: the 44th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Toronto, Canada: October 16, 1997.
18. Aman M, Langworthy K. Pharmacotherapy for hyperactivity in children with autism and other pervasive developmental disorders. J Autism Dev Disord. 2000;30:451-459.
19. Campbell M, Fish B, David R, Shapiro T, Collins P, Koh C. Response to triiodothyronine and dextroamphetamine: a study of preschool schizophrenic children. J Autism Child Schizophr. 1972;2:343-358.
20. Campbell M, Small AM, Collins PJ, Friedman E, David R, Genieser N. Levodopa and levoamphetamine: a crossover study in young schizophrenic children. Curr Ther Res Clin Exp. 1976;19:70-86.21.
21. Birmaher B, Quintana H, Greenhill LL. Methylphenidate treatment of hyperactive autistic children. J Am Acad Child Adolesc Psychiatry. 1988;27:248-251.
22. Yuwiler A, Brammer GL, Morley JE, Raleigh MJ, Flannery JW, Geller E. Short-term and repetitive administration of oral tryptophan in normal men -effects on blood tryptophan, serotonin, and kynurenine concentrations. Arch Gen Psychiatry. 1981;38:619-626.
23. Realmuto GM, August GJ, Garfinkel B. Clinical effect of buspirone in autistic children. J Clin Psychopharmacol. 1989;9:122-125.
24. Schmidt K. The effect of stimulant medication in childhood-onset pervasive developmental disorder-a case report. J Dev Behav Pediatr. 1982;3:244-246.
25. Sporn A, Pinsker H. Use of stimulant medication in treating pervasive developmental disorder. Am J Psychiatry. 1981;138:997.
26. Strayhorn Jr. JM, Rapp N, Donina W, Strain PS. Randomized trial of methylphenidate for an autistic child. J Am Acad Child Adolesc Psychiatry. 1988;27:244-247.
27. Vitriol C, Farber B. Stimulant medication in certain childhood disorders. Am J Psychiatry. 1981;138:1517-1518.
28. Volkmar FR, Stier DM, Cohen DJ. Age of recognition of pervasive developmental disorder. Am J Psychiatry. 1985;142:1450-1452.
29. Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord. 1995;25:283-294.
30. Handen BL, Johnson CR, Lubetsky M. Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord. 2000;30:245-255.
31. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL. Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol. 1992;12:322-327.
32. Fankhauser MP, Karumanchi VC, German ML, Yates A, Karumanchi SD. A double-blind, placebo-controlled study of the efficacy of transdermal clonidine in autism. J Clin Psychiatry. 1992;53:77-82.
33. Williams DT, Mehl R, Yudofsky S, Adams D, Roseman B. The effect of propranolol on uncontrolled rage outbursts in children and adolescents with organic brain dysfunction. J Am Acad Child Adolesc Psychiatry. 1982;21:129-135.
34. Ratey J, Bemporad J, Sorgi P, et al. Brief report: open trial effects of beta-blockers on speech and social behaviors in 8 autistic adults. J Autism Dev Disord. 1987;17:439-446.
35. Fish B, Shapiro T, Campbell M. Long-term prognosis and the response of schizophrenic children to drug therapy: A controlled study of trifluoperazine. Am J Psychiatry. 1966;123:32-39.
36. Campbell M, Anderson LT, Meier M, et al. A comparison of haloperidol and behavior therapy and their interaction in autistic children. J Am Acad Child Psychiatry. 1976;17:640-655.
37. Cohen IL, Campbell M, Posner D, Small AM, Triebel D, Anderson LT. Behavioral effects of haloperidol in young autistic children. An objective analysis using a within subject reversal design. J Am Acad Child Psychiatry. 1980;19:665-677.
38. Naruse H, Nagahata M, Nakane Y, Shirahashi K, Takesada M, Yamazaki K. A multi-center double-blind trial of pimozide (Orap), haloperidol and placebo in children with behavioral disorders, using crossover design. Acta Paedopsychiat. 1982;48:173-184.
39. Anderson LT, Campbell M, Grega DM, Perry R, Small AM, Green WH. Haloperidol in the treatment of infantile autism: Effects on learning and behavioral symptoms. Am J Psychiatry. 1984;141:1195-1202.
40. Anderson LT, Campbell M, Adams P, Small AM, Perry R, Shell J. The effects of haloperidol on discrimination learning and behavioral symptoms in autistic children. J Autism Dev Disord. 1989;9:227-239.
41. Perry R, Campbell M, Adams P, Lynch N, Spencer EK. Long-term efficacy of haloperidol in autistic children: Continuous versus discontinuous drug administration. J Am Acad Child Adolesc Psychiatry. 1989;28:87-92.
42. Ernst M, Magee HJ, Gonzalez NM, Locascio JJ, Rosenberg CR, Campbell M. Pimozide in autistic children. Psychopharmacol Bull. 1992;28:187-191.
43. Campbell M, Adams P, Perry R, Spencer EK, Overall JE. Tardive and withdrawal dyskinesia in autistic children: a prospective study. Psychopharmacol Bull. 1988;24:251-255.
44. Wilmut I, Schnieke AE, McWhir J, Kind AJ, Campbell KHS. Viable offspring derived from fetal and adult mammalian cells. Nature. 1997;385:810-813.
45. McDougle CJ, Holmes JP, Bronson MR, et al. Risperidone treatment of children and adolescents with pervasive developmental disorders: a prospective open-label study. J Am Acad Child Adolesc Psychiatry. 1997;36:685-693.
46. Unis A, Cook E, Vincent J, Gjerde D, Perry B, Mason C, et al. Platelet serotonin measures in adolescents with conduct disorder. Biol Psychiatry. 1997;42:553-559.
47. Barber J, Cross I, Douglas F, Nicholson J, Moore K, Browne C. Neurofibromatosis pseudogene amplification underlies euchromatic cytogenetic duplications and triplications of proximal 15q. Hum Genet. 1998;103:600-607.
48. Potenza MN, Holmes JP, Kanes SJ, McDougle CJ. Olanzapine treatment of children, adolescents, and adults with pervasive developmental disorders: an open-label pilot study. J Clin Psychopharmacol. 1999;19:37-44.
49. Masi G, Cosenza A, Mucci M, Brovedani P. Open trial of risperidone in 24 young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry. 2001;40:1206-1214.
50. McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55:633-641.
51. Hellings JA, Zarcone JR, Crandall K, Wallace D, Schroeder SR. Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. J Child Adolesc Psychopharmacol. 2001;11:229-238.
52. Volkmar FR, Nelson DS. Seizure disorders in autism. J Am Acad Child Adolesc Psychiatry. 1990;29:127-129.
53. Di Martino A, Tuchman RF. Antiepileptic drugs: affective use in autism spectrum disorders. Pediatr Neurol. 2001;25:199-207.
54. Plioplys A. Autism: Electroencephalographic abnormalities and clinical improvement with valproic acid. Arch Pediatr Adolesc Med. 1994;148:220-222.
55. Childs JA, Blair JL. Valproic acid treatment of epilepsy in autistic twins. J Neurosci Nurs. 1997;29:244-248.
56. Damore J, Stine J, Brody L. Medication-induced hypomania in Asperger's disorder. J Am Acad Child Adolesc Psychiatry. 1998;37:248-249.
57. Hollander E, Dolgoff-Kaspar R, Cartwright C, Rawitt R, Novotny S. An open trial of divalproex sodium in autism spectrum disorders. J Clin Psychiatry. 2001;62:530-534.
58. Deonna T, Ziegler AL, Moura-Serra J, Innocenti G. Autistic regression in relation to limbic pathology and epilepsy: report of two cases. Dev Med Child Neurol. 1993;35:166-176.
59. Komoto J, Usui S, Hirata J. Infantile autism and affective disorder. J Autism Dev Disord. 1984;14:81-84.
60. Belsito K, Law P, Kirk K, Landa R, Zimmerman A. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2001;31:175-181.
61. King B, Wright D, Handen B, et al. A double-blind, placebo-controlled study of amantidine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:658-665.
62. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenobarbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80:909-917.
63. Vining EPG, Mellits D, et al. Psychologic and behavioral effects of antiepileptic drugs in children: a double-blind comparison between phenobarbital and valproic acid. Pediatrics. 1987;80:165-174.
64. Campbell M, Anderson L, Small A, Adams P, Gonzalez N, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. J Am Acad Child Adolesc Psychiatry. 1993;32:1283-1291.
65. Zingarelli G, Ellman G, Hom A, Wymore M, Heidorn S, Chicz-DeMet A. Clinical effects of naltrexone on autistic behavior. Am J Ment Retard. 1992;97:57-63.
66. Willemsen-Swinkels SHN, Buitelaar JK, Weijnen FG, Van Engeland H. Placebo-controlled acute dosage naltrexone study in young autistic children. Psychiatry Research 1995;58:203-215.
67. Herman B, Asleson G, Papero P. Acute and chronic naltrexone decreases the hyperactivity of autism. Abstr Soc Neurosci. 1993: Abstract 732.3.
68. Willemsen-Swinkels SHN, Buitelaar JK, Van Engeland H. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study. Biol Psychiatry. 1996;39:1023-1031.
69. Willemsen-Swinkels SH, Buitelaar JK, van Berckelaer-Onnes IA, van Engeland H. Brief report: six months continuation treatment in naltrexone-responsive children with autism: an open-label case-control design. J Autism Dev Disord. 1999;29:167-169.
70. Percy AK, Glaze DG, Schultz RJ, Zoghbi HY, Williamson D, Frost J, Jr., et al. Rett syndrome: controlled study of an oral opiate antagonist, naltrexone. Ann Neurol. 1994;35:464-470.
71. Campbell M, Fish B, Korein J, Shapiro T, Collins P, Koh C. Lithium and chlorpromazine: A controlled crossover study of hyperactive severely disturbed young children. J Autism Child Schizophr. 1972;2:234-263.
72. Buitelaar JK, van der Gaag RJ, van der Hoeven J. Buspirone in the management of anxiety and irritability in children with pervasive developmental disorders: results of an open-label study. J Clin Psychiatry. 1998;59:56-59.
73. Carlsson ML. Hypothesis: is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - serotonin interactions for pharmacotherapy. J Neural Transm. 1998;105(4-5):525-535.
74. Martineau J, Barthelemy C, Cheliakine C, Lelord G. Brief report: an open middle-term study of combined vitamin B6- magnesium in a subgroup of autistic children selected on their sensitivity to this treatment. J Autism Dev Disord. 1988;18:435-447.
75. Kleijnen J, Knipschild P. Niacin and vitamin B6 in mental functioning: a review of controlled trials in humans. Biol Psychiatry. 1991;29:931-41.
76. Geller E, Ritvo ER, Freeman BJ, Yuwiler A. Preliminary observations on the effect of fenfluramine on blood serotonin and symptoms in three autistic boys. N Eng J Med. 1982;307:165-169.
77. Aman MG, Kern RA. Review of fenfluramine in the treatment of the developmental disabilities. J Amer Acad Child Adolesc Psychiatry. 1989;28:549-565.
78. Leventhal BL, Cook EH, Jr, Morford M, Ravitz AJ, Heller W, Freedman DX. Clinical and neurochemical effects of fenfluramine in children with autism. J Neuropsychiatry Clin Neurosci. 1993;5:307-315.
79. Aman MG, Kern RA, Arnold LE, McGhee DE. Fenfluramine and mental retardation. J Am Acad Child Adolesc Psychiatry. 1991;30:507-508.
80. Schuster CR, Lewis M, Seiden LS. Fenfluramine: neurotoxicity. Psyclwpharm Bull. 1986;22:148-151.
81. Horvath K, Stefanatos G, Sokolski KN, Wachtel R, Nabors L, Tildon JT. Improved social and language skills after secretin administration in patients with autistic spectrum disorders. J Assoc Acad Minor Phys. 1998;9:9-15.
82. Sandler AD, Sutton KA, DeWeese J, Girardi MA, Sheppard V, Bodfish JW. Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder. N Engl J Med. 1999;341:1801-1806.
83. Chez MG, Buchanan CP, Bagan BT, et al. Secretin and autism: a two-part clinical investigation. J Autism Dev Disord 2000;30:87-94.
84. Dunn-Geier J, Ho HH, Auersperg E, et al. Effect of secretin on children with autism: a randomized controlled trial. DevMed Child Neurol. 2000;42:796-802.
85. Roberts W, Weaver L, Brian J, et al. Repeated doses of porcine secretin in the treatment of autism: a randomized, placebo-controlled trial. Pediatrics. 2001;107:E71.
86. Coniglio SJ, Lewis JD, Lang C, Burns TG, Subhani-Siddique R, Weintraub A, et al. A randomized, double-blind, placebo-controlled trial of single-dose intravenous secretin as treatment for children with autism. J Pediatr. 2001;138:649-655.
87. Owley T, McMahon W, Cook EH, et al. Multi-site, double-blind, placebo-controlled trial of porcine secretin in autism. J Am Acad Child Adolesc Psychiatry. 2001;40:1293-1299.
88. Aman M. Aberraat Behavior Checklis-Community. East Aurora, NY: Slosson Educational Publications; 1994.